Relaxin reduces susceptibility to post-infarct atrial fibrillation in mice due to anti-fibrotic and anti-inflammatory properties.

[1]  Nassir F Marrouche,et al.  Magnetic resonance imaging of atrial fibrosis: redefining atrial fibrillation to a syndrome , 2017, European heart journal.

[2]  T. Beiert,et al.  Anti-atherosclerotic effects of serelaxin in apolipoprotein E-deficient mice. , 2016, Atherosclerosis.

[3]  D. McManus,et al.  Relation of Atrial Fibrillation in Acute Myocardial Infarction to In-Hospital Complications and Early Hospital Readmission. , 2016, The American journal of cardiology.

[4]  G. Salama,et al.  Relaxin suppresses atrial fibrillation in aged rats by reversing fibrosis and upregulating Na+ channels. , 2016, Heart rhythm.

[5]  A. Noegel,et al.  Deficiency of cyclase-associated protein 2 promotes arrhythmias associated with connexin43 maldistribution and fibrosis , 2016, Archives of medical science : AMS.

[6]  J. R. Groot,et al.  Myocardial infarction, atrial fibrillation and mortality: timing is everything , 2015 .

[7]  U. Hofmann,et al.  Determination of collagen content within picrosirius red stained paraffin-embedded tissue sections using fluorescence microscopy , 2015, MethodsX.

[8]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[9]  P. Ponikowski,et al.  Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. , 2014, Journal of the American College of Cardiology.

[10]  S. Royce,et al.  Serelaxin Is a More Efficacious Antifibrotic Than Enalapril in an Experimental Model of Heart Disease , 2014, Hypertension.

[11]  Philipp Sasse,et al.  Optogenetic activation of Gq signalling modulates pacemaker activity of cardiomyocytes. , 2014, Cardiovascular research.

[12]  N. Frangogiannis,et al.  The inflammatory response in myocardial injury, repair, and remodelling , 2014, Nature Reviews Cardiology.

[13]  J. Díez.  Serelaxin: A Novel Therapy for Acute Heart Failure with a Range of Hemodynamic and Non-Hemodynamic Actions , 2014, American Journal of Cardiovascular Drugs.

[14]  P. Andersen,et al.  New‐Onset Atrial Fibrillation is Associated With Cardiovascular Events Leading to Death in a First Time Myocardial Infarction Population of 89 703 Patients With Long‐Term Follow‐Up: A Nationwide Study , 2014, Journal of the American Heart Association.

[15]  K. Willecke,et al.  The Connexin40A96S mutation from a patient with atrial fibrillation causes decreased atrial conduction velocities and sustained episodes of induced atrial fibrillation in mice. , 2013, Journal of molecular and cellular cardiology.

[16]  Lei Yang,et al.  Relaxin Suppresses Atrial Fibrillation by Reversing Fibrosis and Myocyte Hypertrophy and Increasing Conduction Velocity and Sodium Current in Spontaneously Hypertensive Rat Hearts , 2013, Circulation research.

[17]  Piotr Ponikowski,et al.  Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial , 2013, The Lancet.

[18]  R. Summers,et al.  Relaxin family peptides and their receptors. , 2013, Physiological reviews.

[19]  G. Ambrosio,et al.  Atrial Fibrillation and Mortality in Patients with Acute Myocardial Infarction: A Systematic Overview and Meta-analysis , 2012, Current Cardiology Reports.

[20]  L. Lickfett,et al.  Total Beta-Adrenoceptor Knockout Slows Conduction and Reduces Inducible Arrhythmias in the Mouse Heart , 2011, PloS one.

[21]  X. Jouven,et al.  Atrial Fibrillation and Death After Myocardial Infarction: A Community Study , 2011, Circulation.

[22]  X. Jouven,et al.  Mortality Associated With Atrial Fibrillation in Patients With Myocardial Infarction: A Systematic Review and Meta-Analysis , 2011, Circulation.

[23]  Xiao-Ming Gao,et al.  Relaxin remodels fibrotic healing following myocardial infarction , 2011, Laboratory Investigation.

[24]  P. Gooley,et al.  Membrane receptors: Structure and function of the relaxin family peptide receptors , 2010, Molecular and Cellular Endocrinology.

[25]  M. Metra,et al.  Relaxin: Review of Biology and Potential Role in Treating Heart Failure , 2010, Current heart failure reports.

[26]  S. Hazen,et al.  Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation , 2010, Nature Medicine.

[27]  Ross A. D. Bathgate,et al.  Cardiovascular effects of relaxin: from basic science to clinical therapy , 2010, Nature Reviews Cardiology.

[28]  S. Hohnloser,et al.  Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. , 2009, European heart journal.

[29]  A. Dart,et al.  Reversal of Cardiac Fibrosis and Related Dysfunction by Relaxin , 2009, Annals of the New York Academy of Sciences.

[30]  Yuan Zhang,et al.  Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy. , 2008, Endocrinology.

[31]  E. Masini,et al.  Relaxin induces mast cell inhibition and reduces ventricular arrhythmias in a swine model of acute myocardial infarction. , 2008, Pharmacological research.

[32]  Guy Salama,et al.  Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia , 2007, Nature.

[33]  Ralf Kettenhofen,et al.  Engraftment of engineered ES cell–derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium , 2006, The Journal of experimental medicine.

[34]  Alexander Ghanem,et al.  Connexin30.2 containing gap junction channels decelerate impulse propagation through the atrioventricular node. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[35]  E. Masini,et al.  ©2005 FASEB The FASEB Journal express article 10.1096/fj.04-3664fje. Published online July 11, 2005. , 2022 .

[36]  Xiaojun Du,et al.  Relaxin Reverses Cardiac and Renal Fibrosis in Spontaneously Hypertensive Rats , 2005, Hypertension.

[37]  J. Mak,et al.  Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. , 2004, Endocrinology.

[38]  B. Fleischmann,et al.  Cellular cardiomyoplasty in a transgenic mouse model. , 2002, Transplantation.

[39]  J. Abraham,et al.  CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. , 2000, Journal of molecular and cellular cardiology.

[40]  E. Masini,et al.  Relaxin protects against myocardial injury caused by ischemia and reperfusion in rat heart. , 1998, The American journal of pathology.